# A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109

> **NCT01624532** · PHASE2 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 240 (actual)

## Conditions studied

- Anthrax

## Interventions

- **BIOLOGICAL:** GC1109 or Placebo of GC1109

## Key facts

- **NCT ID:** NCT01624532
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-14
- **Primary completion:** 2022-08-02
- **Final completion:** 2022-12-19
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2023-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624532, "A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01624532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*